【目的】基于网状Meta分析评价中成药联合吸入疗法对儿童支气管哮喘的疗效及安全性。【方法】计算机检索中国期刊全文数据库(CNKI)、中国生物医学文献数据库(CBM)、万方医学数据库(Wanfang Data)、维普信息资源系统(VIP)、Embase、PubMe...【目的】基于网状Meta分析评价中成药联合吸入疗法对儿童支气管哮喘的疗效及安全性。【方法】计算机检索中国期刊全文数据库(CNKI)、中国生物医学文献数据库(CBM)、万方医学数据库(Wanfang Data)、维普信息资源系统(VIP)、Embase、PubMed、Web of Science等数据库中收录的中成药联合吸入疗法治疗儿童支气管哮喘的临床随机对照试验,应用Stata14对数据进行网状Meta分析。【结果】最终纳入28项研究,包括7种中成药,分别为寒喘祖帕颗粒、槐杞黄颗粒、痰热清注射液、小儿肺热咳喘颗粒、喘可治注射液、玉屏风颗粒、珠贝定喘丸。网状Meta分析结果显示,在提高总有效率方面,优选概率排名曲线(surface under the cumulative ranking curve,SUCRA)的概率排序居前3位的依次为痰热清注射液联合吸入疗法、喘可治注射液联合吸入疗法、珠贝定喘丸联合吸入疗法;改善肺功能指标呼气峰值流速(peak expiratory flow,PEF)、第1秒用力呼气容积(forced expiratory volume at one second,FEV1)、FEV1与用力肺活量(forced vital capacity,FVC)的比值(FEV1/FVC)最优的干预措施分别为痰热清注射液联合吸入疗法、寒喘祖帕颗粒联合吸入疗法、珠贝定喘丸联合吸入疗法;对不良反应发生率的SUCRA概率排序的分析结果显示,小儿肺热咳喘颗粒联合吸入疗法可能为副作用最小的干预措施,珠贝定喘丸联合吸入疗法可能为副作用较大的干预措施。【结论】中成药联合吸入疗法较单纯吸入疗法可提高小儿支气管哮喘的有效率及改善肺功能指标,且安全性较好。展开更多
目的:通过总结1例度普利尤单抗联合变应原特异性免疫疗法治疗青春期难治性支气管哮喘的临床资料,提高临床医生对青春期难治性哮喘的认识。方法:回顾性分析我院收治的1例青春期难治性支气管哮喘患儿的临床资料,并进行文献复习。结果:该...目的:通过总结1例度普利尤单抗联合变应原特异性免疫疗法治疗青春期难治性支气管哮喘的临床资料,提高临床医生对青春期难治性哮喘的认识。方法:回顾性分析我院收治的1例青春期难治性支气管哮喘患儿的临床资料,并进行文献复习。结果:该患儿出院后规律雾化,加用度普利尤单抗联合变应原特异性免疫疗法治疗,支气管哮喘及特应性皮炎得到了良好控制,ACT评分、SCOARD评分、PAQLQ评分及肺功能得到明显的改善。结论:1) 度普利尤单抗联合变应原特异性免疫疗法对青春期难治性支气管哮喘疗效显著,同时可以缓解特应性皮炎的临床症状。2) 青春期支气管哮喘患儿的综合管理至关重要,合并其他2型炎症会增加其治疗难度。3) 临床医生在常规治疗的过程中需注重对患儿的健康教育和情绪管理,提高青春期支气管哮喘过渡管理水平,促进全生命周期的呼吸健康管理Objective: To improve the understanding of adolescent refractory asthma by summarizing the clinical data of a case of Dupilumab combined with allergen specific immunotherapy for adolescent refractory bronchial asthma. Methods: The clinical data of an adolescent child with refractory bronchial asthma in our hospital were retrospectively analyzed, and the literature was reviewed. Results: After regular atomization, plus Dupilumab combined with allergen specific immunotherapy, asthma and atopic dermatitis were well controlled, and ACT score, SCOARD score, PAQLQ score lung function were significantly improved. Conclusion: 1) Dupilumab combined with allergen specific immunotherapy has significant effect on refractory adolescent bronchial asthma and can also alleviate the clinical symptoms of atopic dermatitis. 2) Comprehensive management of adolescent children with bronchial asthma is crucial, and the combination of other type 2 inflammation will increase the difficulty of treatment. 3) Clinicians should pay attention to health education and emotional management of children in the process of routine treatment, to improve the transitional management level of adolescent bronchial asthma and promote the respiratory health management of the whole life cycle.展开更多
文摘【目的】基于网状Meta分析评价中成药联合吸入疗法对儿童支气管哮喘的疗效及安全性。【方法】计算机检索中国期刊全文数据库(CNKI)、中国生物医学文献数据库(CBM)、万方医学数据库(Wanfang Data)、维普信息资源系统(VIP)、Embase、PubMed、Web of Science等数据库中收录的中成药联合吸入疗法治疗儿童支气管哮喘的临床随机对照试验,应用Stata14对数据进行网状Meta分析。【结果】最终纳入28项研究,包括7种中成药,分别为寒喘祖帕颗粒、槐杞黄颗粒、痰热清注射液、小儿肺热咳喘颗粒、喘可治注射液、玉屏风颗粒、珠贝定喘丸。网状Meta分析结果显示,在提高总有效率方面,优选概率排名曲线(surface under the cumulative ranking curve,SUCRA)的概率排序居前3位的依次为痰热清注射液联合吸入疗法、喘可治注射液联合吸入疗法、珠贝定喘丸联合吸入疗法;改善肺功能指标呼气峰值流速(peak expiratory flow,PEF)、第1秒用力呼气容积(forced expiratory volume at one second,FEV1)、FEV1与用力肺活量(forced vital capacity,FVC)的比值(FEV1/FVC)最优的干预措施分别为痰热清注射液联合吸入疗法、寒喘祖帕颗粒联合吸入疗法、珠贝定喘丸联合吸入疗法;对不良反应发生率的SUCRA概率排序的分析结果显示,小儿肺热咳喘颗粒联合吸入疗法可能为副作用最小的干预措施,珠贝定喘丸联合吸入疗法可能为副作用较大的干预措施。【结论】中成药联合吸入疗法较单纯吸入疗法可提高小儿支气管哮喘的有效率及改善肺功能指标,且安全性较好。
文摘目的:通过总结1例度普利尤单抗联合变应原特异性免疫疗法治疗青春期难治性支气管哮喘的临床资料,提高临床医生对青春期难治性哮喘的认识。方法:回顾性分析我院收治的1例青春期难治性支气管哮喘患儿的临床资料,并进行文献复习。结果:该患儿出院后规律雾化,加用度普利尤单抗联合变应原特异性免疫疗法治疗,支气管哮喘及特应性皮炎得到了良好控制,ACT评分、SCOARD评分、PAQLQ评分及肺功能得到明显的改善。结论:1) 度普利尤单抗联合变应原特异性免疫疗法对青春期难治性支气管哮喘疗效显著,同时可以缓解特应性皮炎的临床症状。2) 青春期支气管哮喘患儿的综合管理至关重要,合并其他2型炎症会增加其治疗难度。3) 临床医生在常规治疗的过程中需注重对患儿的健康教育和情绪管理,提高青春期支气管哮喘过渡管理水平,促进全生命周期的呼吸健康管理Objective: To improve the understanding of adolescent refractory asthma by summarizing the clinical data of a case of Dupilumab combined with allergen specific immunotherapy for adolescent refractory bronchial asthma. Methods: The clinical data of an adolescent child with refractory bronchial asthma in our hospital were retrospectively analyzed, and the literature was reviewed. Results: After regular atomization, plus Dupilumab combined with allergen specific immunotherapy, asthma and atopic dermatitis were well controlled, and ACT score, SCOARD score, PAQLQ score lung function were significantly improved. Conclusion: 1) Dupilumab combined with allergen specific immunotherapy has significant effect on refractory adolescent bronchial asthma and can also alleviate the clinical symptoms of atopic dermatitis. 2) Comprehensive management of adolescent children with bronchial asthma is crucial, and the combination of other type 2 inflammation will increase the difficulty of treatment. 3) Clinicians should pay attention to health education and emotional management of children in the process of routine treatment, to improve the transitional management level of adolescent bronchial asthma and promote the respiratory health management of the whole life cycle.
